ClinicalTrials.gg
RecruitingNCT05181696RANCH-COVIDUpdated Sep 19, 2024

Retrospective Analysis of Chest X-ray Severity Scoring System of COVID-19 Pneumonia

An observational study in COVID-19 Pneumonia, Sepsis and SARS-CoV-2 Acute Respiratory Disease, sponsored by Osijek University Hospital. Recruiting at 1 site in Croatia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Osijek University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2020; still recruiting 6 years 10 months later.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
200
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The research will be retrospective, and will include all patients who were admitted during 2020 and 2021 in the COVID-19 ICU of University Hospital Center Osijek due to pneumonia caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of chest x-ray infiltrate evolution with changes in laboratory inflammatory parameters and respiratory function parameters will be examined.

Read the detailed description

The research will be retrospective, and will include a review of medical history of all patients admitted in the COVID-19 ICU of the University hospital Osijek during 2020 and 2021. Associated comorbidity, hospital admission date, intubation date, mechanical ventilation, extubation, discharge, and patient final outcome will be recorded for each patient. By analyzing X-rays of the lungs by radiology specialists, inflammatory infiltrates in the lungs will be quantified via the Brixia system, during hospital admission, admission to the Respiratory Center, and during treatment at the Respiratory Center. All patients will have their Sequential Organ Failure Assessment (SOFA) and/or Acute Physiology and Chronic Health Evaluation (APACHE II) values calculated upon admission. Inflammatory parameters (c-reactive protein (CRP), procalcitonin (PCT), interleukine-6 (IL-6), ferritin), red blood cell count, leukocytes, blood urea nitrogen (BUN), arterial blood gases and ventilation parameters on admission to the hospital, admission to the ICU, and on several occasions during treatment in the ICU will be analysed. Also, empirical use of antibiotics, the occurrence of bacterial superinfections, sepsis and organic failure will be noted.

02

Conditions studied

  • COVID-19 Pneumonia
  • Sepsis
  • SARS-CoV-2 Acute Respiratory Disease
  • Pneumonia
  • Multiorgan Failure

Keywords

  • COVID-19
  • Acute respiratory distress syndrome (ARDS)
  • Sepsis
  • Multiorgan Failure
  • Chest X-ray
  • Inflammation
03

In context

Sepsis

2,416 studies on the registry are indexed under Sepsis; 541 are open to participants now.

This study's planned enrollment of 200 is above the median of 150 across 1,162 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Osijek University Hospital is the lead sponsor of 30 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients treated in ICU COVID-19 with a diagnosis of pneumonia will be analyzed retrospectively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pneumonia caused by SARS-CoV-2 virus
  • Admission to the ICU COVID-19 unit

Exclusion criteria

Exclusion Criteria:

  • Patients with lung tumors or history of lung resection
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • COVID-19 pneumonia patients

    Patients treated at the University Hospital Osijek Respiratory Center with pneumonia caused by SARS-CoV-2

    Diagnostic Test: Chest X-ray

Interventions

  • Diagnostic testChest X-ray

    Retrospective analysis of chest x-rays of patients with COVID-19

06

What researchers measure

Primary outcomes

  1. Chest x-ray severity score

    The influence of the dynamics of radiographic changes quantified by Brixia score on the outcome of COVID-19 patients will be examined

    Time frame: 21 days

  2. Inflammatory markers

    The influence of serum levels of inflammatory parameters, and clinical and laboratory indicators of organic failure on chest x-ray severity score will be examined

    Time frame: 21 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, Labrique A, Mohan D. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One. 2021 Mar 4;16(3):e0247461. doi: 10.1371/journal.pone.0247461. eCollection 2021. PubMed 33661992 ↗
  • Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2021 Feb;49(1):15-28. doi: 10.1007/s15010-020-01509-1. Epub 2020 Aug 28. PubMed 32860214 ↗
  • Mahat RK, Panda S, Rathore V, Swain S, Yadav L, Sah SP. The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100727. doi: 10.1016/j.cegh.2021.100727. Epub 2021 Mar 20. Erratum In: Clin Epidemiol Glob Health. 2022 Jan-Feb;13:100991. doi: 10.1016/j.cegh.2022.100991. PubMed 33778183 ↗
  • Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. Radiol Med. 2020 May;125(5):509-513. doi: 10.1007/s11547-020-01200-3. Epub 2020 May 1. PubMed 32358689 ↗
  • Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, Maroldi R. Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. Radiol Med. 2020 May;125(5):461-464. doi: 10.1007/s11547-020-01202-1. Epub 2020 May 1. PubMed 32358691 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for May 2025, 64 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2022
First posted
Jan 6, 2022
StartActual
Jan 1, 2020
Primary completionEst.
May 2025
CompletionEst.
May 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05181696
Lead sponsor
Osijek University Hospital
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Jan 1, 2020
Primary completion
May 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Nenad Nešković, PhD
Contact
nneskov@gmail.com
+395996787250
Ivana Haršanji Drenjančević, PhD
Contact
ihdrenjan@gmail.com
+385915108941
Nenad Nešković, PhD
principal investigator · University Hospital Osijek

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion